S49 Stock Overview
A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Supernus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.40 |
| 52 Week High | US$38.20 |
| 52 Week Low | US$23.80 |
| Beta | 0.84 |
| 1 Month Change | -20.97% |
| 3 Month Change | -13.53% |
| 1 Year Change | -8.70% |
| 3 Year Change | 3.52% |
| 5 Year Change | 88.46% |
| Change since IPO | 614.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| S49 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 4.1% |
| 1Y | -8.7% | -10.7% | 17.2% |
Return vs Industry: S49 exceeded the German Pharmaceuticals industry which returned -10.7% over the past year.
Return vs Market: S49 underperformed the German Market which returned 17.2% over the past year.
Price Volatility
| S49 volatility | |
|---|---|
| S49 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: S49 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: S49's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 674 | Jack Khattar | www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.
Supernus Pharmaceuticals, Inc. Fundamentals Summary
| S49 fundamental statistics | |
|---|---|
| Market cap | €1.65b |
| Earnings (TTM) | €67.78m |
| Revenue (TTM) | €607.28m |
24.2x
P/E Ratio2.7x
P/S RatioIs S49 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S49 income statement (TTM) | |
|---|---|
| Revenue | US$661.82m |
| Cost of Revenue | US$77.91m |
| Gross Profit | US$583.91m |
| Other Expenses | US$510.05m |
| Earnings | US$73.87m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.32 |
| Gross Margin | 88.23% |
| Net Profit Margin | 11.16% |
| Debt/Equity Ratio | 0% |
How did S49 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 01:41 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| David Buck | B. Riley Securities, Inc. |
| John Tanner | Cantor Fitzgerald & Co. |